Clinical Digest: Recent Clinical Trials on MERS
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to MERS. These trials are organized by their release dates for your convenience. (Last updated on: 2025-05-02)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that empowers you to read articles, write articles, get answers, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on MERS
| Clinical Trial | Contact(s) | Date | |
|---|---|---|---|
| 1 | An Exploratory Study of A General Anesthesia Regimen for Deep Brain Electrical Stimulation in Patients with Parkinson’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Patients who meet the enrollment criteria and voluntarily join this study will be admitted to the operating room on the day of surgery, and will receive endotracheal intubation under general anesthesia. Induction will be conducted with sufentanil 0.2~0.3ug/kg, rocuronium bromide 0.6mg/kg and propofol 1~2 mg/kg. After successful intubation, mechanical ventilation will be provided with a fresh air flow of 2.0 L/min, a tidal volume of 6~8ml/kg and a respiratory rate of 10~12 times/min to control the end-tidal carbon dioxide between 35~45mmHg. Following that, … |
JIE TIAN; | 2024-10-29 |
| 2 | A Comparative Evaluation of Specimen Adequacy of A Traditional Nasopharyngeal Swab As Compared to Nasopharyngeal Saline Wash, Saliva, and Serum to Test for Respiratory Viruses and Antibody Response PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: Respiratory tract infections (RTIs) are prevalence community diseases and is the third leading cause of death worldwide. Rapid diagnosis of RTIs is essential as it drives decision points such as treatment, disposition, and containment. According to recent CDC (The Centers for Disease Control and Prevention) updates, nasopharyngeal swabbing is the preferred method of specimen collection for most RTIs such as SARS-COV-2. This process is invasive and traumatizing for patients as it requires probing (20 seconds) of the posterior nasopharynx with swab applicator. In some cases, … |
THANH NGUYEN; | 2023-08-21 |
| 3 | The Impact of Anesthesia and Positioning on Cerebral Blood Flow and Pressure in Patients Undergoing Laparoscopic Surgery: An Observational Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this observational study was to understand the effect of ReverseTrendelenburg position, Trendelenburg position on intracranial pressure and carotid blood flow in patients undergoing laparoscopic surgery. The main question it aims to answer is: Does ReverseTrendelenburg position increase common carotid artery (CCA) flow, optic nerve sheath diameter (ONSD); does Trendelenburg position decrease CCA flow, ONSD. |
XIAGUANG DUAN; | 2023-02-01 |
| 4 | Rhomboid Intercostal Block with Subserratus Plane Block in Bariatric Surgery: A Three-arm Prospective Randomized Comparative Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Standard analgesic techniques such as patient-controlled analgesia (PCA) and continuous epidural analgesia (CEA) are effective but associated with considerable side effects, including nausea, hypotension, and respiratory depression. This study aimed to evaluate the efficacy and safety of the rhomboid intercostal block combined with subserratus plane block (RISS) compared to PCA and CEA for postoperative analgesia in bariatric surgery. |
XIAGUANG DUAN; | 2023-01-01 |
| 5 | Phase-I, Single Center, Randomized, Dosage Finding Study, to Evaluate The Safety, Tolerability, and Immunogenicity of A Prophylactic COVID-19 PDNA Vaccine After Multiple Ascending Doses in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A pneumonia of unknown cause detected in Wuhan, China, was first reported in December 2019. On 08 January 2020, the pathogen causing this outbreak was identified as a novel coronavirus 2019. The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020. On 12 February 2020, the virus was officially named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the WHO officially named the disease caused by SARS-CoV-2 as coronavirus disease 2019 (COVID-19). On 11 March 2020, the WHO upgraded the status of the COVID-19 outbreak from epidemic to pandemic, … |
IMAN ALMANSOUR; | 2022-11-20 |
| 6 | Choice of Anesthesia in Microelectrode Recording Guided Deep Brain Stimulation for Parkinson’s Disease (CHAMPION)：A Randomized Controlled, Non-Inferiority Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Subthalamic nucleus (STN)-deep brain stimulation (DBS) under general anesthesia has been applied to PD patients who cannot tolerate awake surgery, but general anesthesia will affect the electrical signal in microelectrode recording (MER) to some degree. This study is a prospective randomized controlled, noninferiority study, open label, endpoint outcome evaluator blinded, … |
RUQUAN HAN; | 2022-11-01 |
| 7 | A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess The Safety, Tolerability and Pharmacokinetics Profile of Single and Multiple Ascending Doses of FB2001 for Inhalation in Healthy Chinese Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: FB2001 is a novel inhalable preparation being developed for COVID-19 treatment. A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics Profile of Single and Multiple Ascending Doses of FB2001 in Healthy Chinese Adults |
XIN LI; | 2022-10-21 |
| 8 | Comorbidities And Complications Associated With Covid-19 Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the spectrum of comorbidities and complications and its impact on the clinical outcome in hospitalized patients with coronavirus disease 2019 (COVID-19). |
MAHMOUD GAMAL HUSSEIN; | 2022-08-25 |
| 9 | Median Effective Concentration (EC50) of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients With Parkinson’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Dexmedetomidine (DEX) sedation is widely used in deep brain stimulation implantation (DBSI) of patients With Parkinson’s disease. However, intraoperative application of DEX may affect the discharge activity of deep brain nuclei and reduce the discharge frequency of Subthalamic nucleus (STN) neurons. At present, there is still a lack of prospective intervention research to explore the optimal dose that does not affect MER mapping in patients with Parkinson’s disease. The present study uses the Dixon and Massey up-and-down method to analyze the EC50 of DEX in patients with PD undergoing STN-DBS sedation, … |
RUQUAN HAN; | 2022-05-31 |
| 10 | Crowdsourcing An Open COVID-19 Chest Radiograph Imaging Repository for Artificial Intelligence Research PF:9 Related Papers Related Patents Related Grants Related Experts View Highlight: The objectives of this project are to (1) assemble a crowdsourced, de-identified radiographic repository; and (2) train and validate existing COVID-NET deep learning diagnostic models. |
DEXTER HADLEY; | 2022-04-14 |
| 11 | Calcifediol in The Treatment of COVID 19. Modification of Therapeutic Response By Best Available Treatment or Other Treatment or Clinical Variables PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Patients hospitalized with COVID-19 treated with calcifediol during the first outbreaks of the pandemic (until the first vaccinations) are compared with the aim of determining the therapeutic, clinical, functional, and biochemical variables that modify the response (admission to ICU or death) to calcifediol during hospitalization for COVID 19 |
LUIS M ENTRENAS COSTA; | 2022-04-01 |
| 12 | An Open Label Evaluation Phase 1 Trial of The Safety and Pharmacokinetics of MRX-2843 in Adolescents and Adults With Relapsed/Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Mixed Phenotype Acute Leukemia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts. |
MELINDA PAULEY; | 2022-04-01 |
| 13 | Clinical and Virological Characterization of Severe Acute Respiratory Infection Using PCR-Based Methods and Metagenomic Sequencing: A National Registry in Saudi Arabia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: SARI is a major public health problem in Saudi Arabia and leads to considerable morbidity and mortality. Most SARI-related mortality occurs in patients admitted to ICUs across the country. RVIs alone and as precipitating causes of bacterial co-infections are under-recognized as causes of critical SARI. Therefore, data regarding the role of RVIs in critically ill patients with SARI in Saudi Arabia are greatly needed to fill the current gaps with respect to pathogens, disease pathogenesis, current treatment approaches, and clinical outcomes. In the VERIFY multicenter national registry, … |
YASEEN ARABI; | 2022-03-20 |
| 14 | Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Reports of long-lasting symptoms of COVID-19 are increasing, but little is known about the prevalence of risk factors or whether it is possible to predict a prolonged course at disease onset. Prolonged COVID is characterized on the basis of symptoms such as fatigue, headache, dyspnea, and anosmia present for weeks, with older age, high body mass index, and female sex being more susceptible. Accordingly, and in the absence of specific treatments, the present study seeks to establish a treatment protocol for Post-COVID syndrome through the application of the dietary supplement VIUSID, due to its anti-inflammatory and immunomodulatory effect, … |
CATALYSIS SL | 2022-02-15 |
| 15 | The Impact of Intrathecal Morphine Versus Continuous Epidural Analgesia on Return of Bowel Function in Patients Undergoing Laparoscopic Ileal Conduit : A Prospective, Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims to compare the effects of intrathecal morphine (ITM) and continuous epidural analgesia (CEA) on bowel function recovery after Bricker surgery.This study was a prospective, randomized controlled trial that included 72 patients with bladder cancer undergoing elective Bricker surgery, who were randomly assigned to either the ITM group (n=36) or the CEA group (n=36). Postoperatively, patients in both groups received either ITM or CEA for pain management, and postoperative bowel function recovery time, pain scores, PONV, itching, and other indicators were recorded. |
XIAGUANG DUAN; | 2022-01-25 |
| 16 | A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate The Safety, Tolerability, and Pharmacokinetics of FB2001 in Healthy Subjects PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: In the first human clinical trial conducted in the United States, single and multiple dosing of FB2001 in multiple dose groups were partially completed，and FB2001 demonstrated good safety and tolerability. The bridge study of FB2001 will be conducted in China to evaluated the safety and PK of FB2001 in healthy Chinese population. This is a randomized, double-blind, placebo-controlled study of single and multiple dosing. |
YUN LIU; | 2021-12-29 |
| 17 | A Phase 1a Safety, Acceptability and Pharmacokinetics Study of Q-Griffithsin Intranasal Spray for Broad-spectrum Coronavirus Pre-exposure Prophylaxis: A Study of The PREVENT-COVID-19Program PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is the first-in-human clinical study to see if a single dose of an investigational nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated and acceptable for use by healthy adults 18 to 60 years of age. |
KENNETH PALMER; | 2021-11-11 |
| 18 | Clinical Presentations and Outcomes of Patients With Covid-19 Pneumonia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims at determining clinical presentations and outcomes of patients with covid-19 pneumonia and also follow up of patients for up to 6 months to detect possibility of post covid fibrosis |
GHADA MOHAMED BAHY; | 2021-11-01 |
| 19 | Outcomes of Diabetes In Hospitalized COVID-19 Patients At Assiut University Hospital PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronavirus disease (COVID-19), a global pandemic affecting the whole world and taking the lives of millions. The majority of fatalities occur in the elderly specially in the presence of chronic diseases such as diabetes mellitus (DM), hypertension, obesity, cardiovascular disease, chronic kidney disease and cancer. |
MARTINA SAAD LAMEY; | 2021-11-01 |
| 20 | An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for The Treatment of Severe CoVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Granula as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this adaptive, randomized,double-blind,controlled trial will evaluate the efficacy and safety of Yinhu Qingwen Granula in patients hospitalized with severe CoVID-19. |
ZHONG WANG; | 2021-11-01 |
| 21 | Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in The Treatment of Mild / Common CoVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally. Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Decoction as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this randomized,three-arm controlled, … |
ZHONG WANG; | 2021-10-01 |
| 22 | Study to Evaluate The Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study is divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage. |
INOVIO PHARMACEUTICALS | 2021-06-21 |
| 23 | Gender Differences in Stroke With COVID-19: Epigenetic and Biochemical Study of ACE2 Receptor and Relationship With Rehabilitative Outcome PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The new coronavirus SARS-CoV-2, causes the COVID-19 infection, which showed a form of neurovirulence involving the Central and peripheral Nervous Systems [Baig et al, 2020]. In a mouse model for human ACE2 expression, the virus entered the brain mainly through the olfactory bulb pathway [Netland et al, 2008], with an encephalic invasion uniformly lethal even with low viral doses and without lung involvement. The death of the animal was reasonably related to neuronal dysfunction/death in cardiorespiratory bone marrow centers, while the absence of ACE2 prevented severe encephalopathy. Men has a highly frequency of severe and lethal COVID-19, … |
IRENE GIOVANNA APRILE; | 2021-06-10 |
| 24 | Pilot Study of Convalescent COVID-19 Plasma Transfusion in Severe COVID-19 Patients at A Type A Teaching Hospital in Jamaica PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Corona virus Disease 2019 (COVID-19) can be a severe respiratory illness caused by Severe Acute Respiratory Syndrome (SARS-CoV2) for which there is no standard treatment in affected persons nor a vaccine to prevent the infection. The investigators propose to test whether the use of Convalescent plasma given to patients with severe COVID-19 disease will decrease risk of death, decrease use of ventilatory support decrease biomarkers of inflammation and improve measures of viral replication compared with controls subjects who were not transfused.Convalescent plasma, … |
GILIAN G WHARFE; | 2021-06-01 |
| 25 | Disease Registry for Pregnant Women With Suspected COVID-19 or Confirmed SARS-CoV-2 and Their Neonates PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The in-utero exposure of acute viral infection in some instances is proven to have short- and long-term neonatal effects during the postnatal and childhood period and the Zika virus, measles, mumps, and rubella are few examples. COVID-19 is caused by a novel coronavirus strain of unknown consequences. The main purpose of this registry is to collect baseline data and help to establish future studies and hypothesis generation. In addition, … |
SALWA ABO YAQOUB; | 2021-05-25 |
| 26 | The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients- A Double Blind Placebo Controlled Randomized Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronavirus Disease 19 (COVID-19) is a worldwide pandemic and a major global health concern which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The newly emerged Coronavirus disease 2019 (COVID-19), which was first identified in Wuhan, China, has swept through 219 countries, killing a staggering number of people. According to WHO reports, the number of deaths had risen to 3,155,168by March 30, 2021, out of 149,910,744 confirmed cases. In Bangladesh, the outbreak has infected over 745,322confirmed cases, with over 11,053 deaths reported. Though the patient may be asymptomatic or present with mild symptoms, … |
SHOHAEL MAHMUD ARAFAT; | 2021-05-15 |
| 27 | Diagnostic Accuracy of Chest X-ray in Coronavirus Disease 2019 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: to identify the diagnostic accuracy of chest X-ray in diagnosis of Coronavirus disease19 . |
MOHAMED ABDELWAHAB ELSADEK IBRAHIM; | 2021-05-01 |
| 28 | Spa Rehabilitation, Antioxidant and Bioenergetic Supportive Treatment of Patients With Post-Covid-19 Syndrome PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Our hypothesis – that 21 days of mountain spa rehabilitation with ubiquinol supplementation could to accelerate regeneration of patients with post-COVID-19 syndrome, based on the improving platelet mitochondrial bioenergetic, decreasing of oxidative stress and improving of antioxidants protections of patients with post-COVID-19 syndrome. |
COMENIUS UNIVERSITY | 2021-05-01 |
| 29 | Based on The Theory of Body Constitution of Chinese Medicine and Combination of Prescription and Syndrome to Improve COVID-19 Susceptible Body Constitution of Residents in Hong Kong PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Chinese medicine has been used for thousands of years in the treatment of epidemic diseases. Through the long-term struggle with the epidemic, Investigators have accumulated and explored a lot of prevention and control experience. According to recent reports, Chinese medicine plays an important role in the treatment of COVID-19. For example. Therefore, it is of great clinical significance to further develop the prevention of COVID-19 by Chinese medicine. According to the 《Diagnosis and treatment of COVID-19》published by National Health Committee and the experience of professional TCM physician, although the disease is generally susceptible, … |
FENG YIBIN; | 2021-04-30 |
| 30 | Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of A Platform Trial to Sequentially Investigate Immunotherapy Combinations for The Augmentation of Immune Responses PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radiation therapy alone). |
ATIF KHAN; | 2021-04-21 |
| 31 | Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest Pro-Health Multi-Protection (Crest, USA), or Listerine Zero (Johnson and Johnson, USA). Study participants will be asked to rinse/gargle with 10-20ml (according to the rinse instructions) of the assigned solutions 4 times per day, for 30-60 seconds, for 4 weeks. |
STUART A GANSKY; | 2021-03-31 |
| 32 | A Phase 2 Randomized, Double-blinded Trial to Evaluate The Efficacy and Safety of Human Anti-SARS-CoV-2 Plasma for Early Treatment of COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as early treatment. Participants will be randomized 2:1 to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or control (albumin 5%). This study will investigate the potential of convalescent plasma (CP) to reduce severity of and/or help treat SARS-CoV-2 disease in patients with mild disease. |
ANDREW EISENBERGER; | 2021-03-12 |
| 33 | Body Composition Study in Critically Ill Patients-Extended to COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Muscle loss (ultrasound quadricep muscle) and muscle strength (handgrip and knee extension strength) will be compared between COVID-19 and non COVID-19 critically ill patients. |
UNIVERSITY OF MALAYA | 2021-03-05 |
| 34 | A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
CONOR STEUER; | 2021-02-24 |
| 35 | INHALEd Unfractionated HEParin for The Treatment of Hospitalized Patients With COVID-19 Pneumonia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Randomized, placebo controlled study to determine if nebulized heparin may reduce the need for mechanical ventilation in hospitalized patients with the novel coronavirus, also known as COVID-19. This will be a part of a larger meta-trial. |
THOMAS SMOOT; | 2021-02-22 |
| 36 | Phase 1b/2a Evaluation of The Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Study Objectives: 1. To evaluate the safety and tolerability of oral SYN-004 in adult allogeneic HCT (allo-HCT) recipients who develop fever after conditioning therapy and are treated with IV β-lactam antibiotics meropenem (MER), piperacillin tazobactam (PIP/TAZO), or cefepime (FEP). 2. To evaluate potential absorption of oral SYN-004 into the systemic circulation of allo-HCT recipients and potential SYN-004-mediated alterations to systemic levels and efficacy of IV MER, PIP/TAZO or FEP. 3. To evaluate potential protective effects of SYN-004 on the intestinal microbiome of allo-HCT recipients treated with IV MER, … |
SYNTHETIC BIOLOGICS | 2021-02-15 |
| 37 | HYPERTONIC SALINE COATED FACE MASK FOR REDUCING RESPIRATORY SYMPTOM SEVERITY IN PATIENTS WITH COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Rationale: Coronavirus disease 2019 (COVID-19) is spreading rapidly in the world with no proven effective therapy to date. Some patients with COVID-19 develop sever respiratory disease requiring ICU care. There is in vitro evidence that hypertonic saline (HTS) may be beneficial in reducing the inflammatory component in similar viral illnesses. Objective: To assess whether wearing a face mask sprayed with HTS (in addition to other COVID-19 treatments) leads to decreasing the severity of the respiratory symptoms resulting from COVID-19. Study design: Multi-centre trial Study population: Any patient older than 18 years of age with confirmed COVID-19 diagnosis who has any of the following respiratory symptoms or signs: – cough, – shortness of breath, – tachypnea (respiratory rate of 20 breaths / minute or more), – hypoxemia (O2 saturation 90% or less on room air) Intervention: Participants will be asked to wear a face mask for 20-30 minutes every 6 hours for the duration of their respiratory symptoms and/or signs. This inside surface of the face mask will be sprayed with 10-15 ml of HTS and allowed to air dry before the participant is permitted to wear it. A new face mask will be given to the patient every 24 hours. All participants will continue to receive their other COVID-19 treatments as per local hospital guidelines. Main study parameter: Improvement of the respiratory symptoms and signs on repeated measurement. Nature and extent of the burden and risks associated with participation, benefit: The burden of COVID-19 is very severe world wide. The trial duration is 3 months, with potential extension if deemed needed by interim analysis at the end of 3 months. There are no additional risks for participation in this study as only face masks will be used with no additional medications being given to the participants. In the future, the results of this study could lead to improved care for COVID-19 patients. |
ALI ALSHANQEETI; | 2021-02-01 |
| 38 | Prospective Two-arm Study of Fertility in Men With COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: COVID-19 infection is hypothesized to have a potentially negative effect on male fertility through direct damage to the testes. The current trial is aimed at investigating the effect of SARS-CoV-2 on fertility and determining if viral bodies are capable of directly damaging testicular cells |
DMITRY ENIKEEV; | 2021-01-18 |
| 39 | SARS-CoV-2 Infections in Children and Potential Fecal-oral Transmission PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The clinical courses of COVID-19 in children are reportedly mild, and may therefore readily escape diagnosis. Prolonged intestinal virus shedding has been reported in children, thus rendering the pediatric population a potentially important source of virus transmission. However, the infectious potential of SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) excreted in the stool has remained enigmatic. The investigators hypothesize that stools carrying the virus can represent a source of infection, at least in a proportion of instances, … |
MERYL HAAS; | 2021-01-06 |
| 40 | Study of Bronchoalveolar Lavage in Patients Recovered From COVID-19 Pneumonia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronaviruses such as SARS-CoV2, MERS-CoV, and SARS-CoV can cause significant morbidity and mortality in infected persons. Lung is the most common site of infection for these viruses, which may manifest as acute respiratory distress syndrome and mortality. Pulmonary involvement is also responsible for the high viral transmission The aim of this study is to evaluate BAL in post-acute COVID-19 patients for:Cytological and cellular patterns. Microbial analysis for possibility of presence of bacterial, mycobacerial or fungal co-infection.PCR for corona virus |
MOHAMED ABD ELMONIEM MOHAMED; | 2021-01-01 |
| 41 | Impact of COVID-19 Infection on The Course of Pregnancy and Fetal-neonatal Outcomes PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: COVID-19, the coronavirus responsible for the pandemic that began at the end of 2019 in China, spreads through respiratory droplets and direct contact. The most common symptoms of the disease include fever, cough, asthenia or myalgia, wheezing and headache, and the most serious complication is acute respiratory distress syndrome (ARDS). The new coronavirus has continued to spread to multiple countries and continents so much so that the epidemic was declared a Public Health Emergency of International Interest (PHEIC) by the World Health Organization (WHO) on January 30, 2020. In the first phase of emergency worldwide, … |
MADDALENA MORLANDO; | 2020-12-28 |
| 42 | Efficacy and Safety of Direct Anti HCV Drugs in The Treatment of SARS-COV-2 (COVID-19) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: COVID 19 which started from a zoonotic transmission related to crowded markets was confirmed to have a high potential for transmission to close contacts on 20 January 2020 by the National Health Commission of China and it was announced as a pandemic by the WHO on 11 March 2020. There is currently no clinically proven specific antiviral agent available for SARS-CoV-2 infection. Supportive treatment, including oxygen therapy, conservation fluid management, and broad-spectrum antibiotics to cover secondary bacterial infection, remains the most important management strategy. Interestingly, … |
MAHMOUD ELBENDARY; | 2020-12-28 |
| 43 | Clinical Trial of Convalescent Plasma Administration As Adjunct Therapy for COVID-19 (Uji Klinik Pemberian Plasma Konvalesen Sebagai Terapi Tambahan COVID-19) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Convalescent plasma (CP) has been the subject of increasing expectation for treating coronavirus disease 2019 (COVID-19). Reports on CP transfusion have shown promising clinical improvements without serious adverse events. To date, most studies focused on reporting CP treatment in patients with severe COVID-19, but only a few addressed benefits on less severe disease. The vast majority of studies reporting COVID-19 infection and treatment have come from earlier affected countries with established health systems and research infrastructure, while very few are from low- and middle-income countries (LMICs). Nonetheless, … |
DAVID H MULJONO; | 2020-12-01 |
| 44 | Disinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract By Controlled Ethanol Vapor Inhalation Combined With Oral Asprin PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Since ARDS is a major complication of COVID – 19 with subsequent formation of non-cardiogenic pulmonary edema , worsening the oxygenation of the patients and foamy and even bloody sputum formation, … |
MANSOURA UNIVERSITY | 2020-12-01 |
| 45 | Post Covid Syndrome: Clinical Pattern and Functional Assessment PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Aim(s) of the Research : 1. Identify post covid symptoms 2. prevalance of post covid syndrome among survivours |
MOSTAFA MAHMOUD; | 2020-12-01 |
| 46 | Virtual Reality Intervention Alleviates Dyspnea in Patients Recovering From COVID Pneumonia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The present COVID-19 Virtual Reality (COVVR) clinical study is performed to test the hypothesis that an immersive virtual reality (iVR)-based Digital Therapeutics (DTx), would alleviate dyspnea by improving breathing comfort in patients recovering from COVID-19 pneumonia presenting with persistent dyspnea. We will further evaluate participants’ perceived awareness of and agency over their breathing movements. Finally, we will track patients’ perceived benefits related to the iVR intervention and the feasibility of using COVVR in the clinic or at home. |
OLAF BLANKE; | 2020-11-26 |
| 47 | Therapeutic Study to Evaluate The Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled Related Papers Related Patents Related Grants Related Experts View Highlight: This is a phase 1 clinical trial to verify the safety and efficacy of DW-MSC in COVID-19 patients. A total of 9 subjects are randomly allocated. Subjects who meet the final inclusion and exclusion criteria are randomized to the test groups (low-dose group and high-dose group) or control group (placebo group) in a ratio of 1:1:1. Subjects assigned to the test groups were administered intravenously once with 5 x 10^7cells of DW-MSC for the low-dose group or 1 x 10^8cells for the high-dose group after registration. Subjects assigned to the control group were administered with placebo in the same manner as the test drug (DW-MSC). At this time, all of the existing standard co-treatment are allowed. DW-MSC is adjunct therapy to standard therapy. This clinical trial is a double-blind trial, in which a randomized method will be used. To maintain the double-blindness of the study, statistician who do not participate in this study independently generate randomization code. Subjects will be randomized to the test groups (low-dose group and high-dose group) or the control group (placebo group) in a 1:1:1 ratio. After the completion of the trial, the randomization code will be disclosed after unlocking the database and unblinding procedures. Follow Up period: observed for 28 days after a single administration |
INA RESPOND | 2020-11-14 |
| 48 | Evaluation of The Efficacy, Safety and Tolerability of Alisporivir for The Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19). A Randomised, Open-label, Proof of Concept, Phase 2 Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: COVID-19 is a viral respiratory and systemic disease that has been rapidly spreading globally since the first cases were reported in December 2019 and has now become pandemic. The causative agent of COVID-19 was identified as a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, first designated as 2019-nCoV). The disease manifestations of COVID-19 can range from mild, self-resolving respiratory disease to severe pneumonia, ARDS, multiorgan failure, and ultimately death. In early reports, … |
JEAN-MICHEL PAWLOTSKY; | 2020-11-01 |
| 49 | Evaluating Effectiveness of Convalescent Plasma and Factors Influencing Therapeutic Outcome in Hospitalized Patients With COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Multicenter retrospective cohort study from June to August 2020 on hospitalized COVID-19 patients admitted to Al-Hakeem and Al-Amal hospital in Al-Najaf Governorate, Iraq, in order to evaluating the effectiveness of plasma therapy in hospitalized patients with COVID-19 and analyzing factors that affect therapeutic outcome, either related to patients or related to donors. |
ZAINAB HADI IBADI; | 2020-11-01 |
| 50 | The Value of Colloidal Silver in The Treatment of COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases. Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I |
RIADH BOUKEF; | 2020-11-01 |
| 51 | Studies on The Differential Expression of Cytokines, Transcriptome and MiRNA in The Context of COVID-19 Infection in Egyptian Community PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this effort is to study host-pathogen interaction in Egyptian patients infected with COVID-19. The investigators will perform genome-wide miRNA and transcriptome screens in the infected patients along with healthy ones for comparison. All types of cytokines play pivotal roles in immunity, including the responses to different viral infections. Therefore, The investigators will study the cytokines profile in response to that infection. By comparing miRNA and transcriptome screens along with cytokines profiles, an important molecule might be identified that could play role in the inhibition of the COVID-19 outbreak. In addition, … |
MOHAMMED ALI AHMED EID; | 2020-10-04 |
| 52 | Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) – (PROVID-CAPNETZ) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The pandemic triggered by the new SARS-CoV-2 presents the German health system with previously unknown challenges. There are currently no effective therapies for the treatment of the SARS-CoV-2 lung disease Covid-19. The aim of the joint project PROVID is to draw conclusions from the often very different clinical appearance of infections with the SARS-CoV-2 pathogen in order to improve patient care through targeted clinical management. The effects of infections with the SARS-CoV-2 pathogen are wide-ranging and include a spectrum from symptomlessness to infections of the upper respiratory tract, … |
HANNOVER MEDICAL SCHOOL | 2020-10-01 |
| 53 | A Randomized, Triple-blind, Placebo-controlled, Clinical Trial on The Diagnostic Performance of Gluten Immunogenic Peptides in The Evaluation of Gluten-free Diet Adherence: The GRRES Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the GRRES study is to assess the clinical usefulness of urinary gluten immunogenic peptides test as a marker of gluten-free diet adherence using the rapid immunochromatographic assay based on anti-gliadin 33-mer monoclonal antibodies. |
CARLO CATASSI; | 2020-10-01 |
| 54 | Study of The P2Et Extract Obtained From Caesalpinia Spinosa in The Symptomatic Treatment of Subjects With COVID-19 at The Hospital Universitario San Ignacio, Colombia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Antioxidants, and particularly polyphenols, have shown protection in respiratory pathologies, which is related to the decrease in the severity of the clinical picture and suppression of inflammation. This suppression of inflammation may be related to the inhibition of NF-kB polyphenols, where its activation is related to the stimulation of 150 stimuli including cytokines (IL-1β, IL-6, THF-α, GM-CSF, MCP-1), TLRs, among others. There may be other additional mechanisms that can help control virus-induced respiratory pathologies, … |
HOSPITAL UNIVERSITARIO SAN IGNACIO | 2020-09-30 |
| 55 | Evaluation of Cell-mediated and Humoral Immunity Following COVID-19 in Pregnancy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The proposed study is designed to investigate if and how pregnant women infected with Coronavirus Disease-19 (COVID-19) infection go on to develop long-term immunity. In December 2019, a group of people in Wuhan, China presented with symptoms of a pneumonia of an unknown cause that led to the discovery of a new coronavirus called COVID-19. COVID-19 has caused a global pandemic with 7,140,000 confirmed cases and 418,000 deaths as of 13th June 2020. In the United Kingdom (UK), there have been 294,000 cases and 41,662 deaths as of 13th June 2020. In humans, … |
NISHEL M SHAH; | 2020-09-16 |
| 56 | Intravenous Immunoglobulins for The Treatment of Covid-19 Patients: A Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The current project is based on the immunological studies covering the potential of disease induced immunoglobulins as treatment regime. We would be able to generate the concentrated antibodies specific against coronavirus (Covid-19). These antibodies can be used as serum therapy. Aside from a Covid-19 vaccine, antibodies from recovered patients could provide a short-term passive immunization to the disease. Those antibodies can be extracted from the blood serum of surviving patients and then injected into infected people. Passive immunization usually lasts for a few weeks or months, after which those borrowed or donated antibodies, … |
FRIDOON JAWAD AHMAD; | 2020-09-15 |
| 57 | A Randomized, Placebo-controlled Study of The Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers. |
NEUROACTIVA | 2020-09-15 |
| 58 | Various Molecular Markers With Predictive and Prognostic Significance in COVID-19 Outcome PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: There is a current worldwide outbreak of the novel coronavirus Covid-19 which originated from Wuhan in China and has now spread to 6 continents including 210 countries. There is still a lack of any report about severe acute respiratory syndromes (SARS-CoV-2) genetic polymorphisms which are associated with the susceptibility to infection. In addition, … |
MAHMOUD ELBENDARY; | 2020-09-10 |
| 59 | A Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With Lymphocytopenia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: It is our hypothesis that a course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and severity of infection (secondary objectives) compared to untreated individuals in the same hospital with comparable lymphocytopenia. After screening, hospitalized patients with COVID-19 and lymphocytopenia who meet the inclusion criteria will receive Ta1 (1.6 mg) administered subcutaneously (SC) daily for 1 week. Individuals in the control arm will be followed on the identical protocol but will not receive daily Ta1. |
ELEFTHERIOS MYLONAKIS; | 2020-09-10 |
| 60 | Psychological Impact of Admission With Covid-19 During The SARS-CoV-2 Pandemic: Naturalistic Cohort Study With A Digital Intervention PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Studies have shown that admission to hospital during a coronavirus epidemic is associated with increased levels of anxiety, depression and panic disorder. During the SARS-CoV-2 pandemic in North London the Royal Free Hospital admitted over 500 patients with Covid-19. As part of the standard of care, these patients are screened at 8 weeks post discharge for signs of anxiety and depression. The Feeling Good app is a NHS approved digital application which utilises applied relaxation, … |
ROYAL FREE HOSPITAL NHS FOUNDATION TRUST | 2020-08-31 |
| 61 | SARS-COV2 Pandemic Serosurvey and Blood Sampling PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Respiratory virus outbreaks and pandemics, such as SARS, MERS, and the new SARS-COV2 virus, have major impacts worldwide. Researchers must act quickly to learn about the exposures and immunity in the general population. This can be done by studying people s blood serum to find those with antibodies to the virus. This knowledge can help in current and future pandemics. In this study, … |
MATTHEW J MEMOLI; | 2020-08-26 |
| 62 | Trial of Silymarin in Adults With COVID-19 Pneumonia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A randomized placebo controlled trial to assess the clinical outcome in COVID-19 Pneumonia following administration of Silymarin owing to its role as a p38 MAPK pathway inhibitor and its antiviral, anti-inflammatory and anti-oxidant effects |
KHALED MOHAMMED KORANY SALEM; | 2020-08-16 |
| 63 | Evaluation of The Evolution of Pregnancies in The First Trimester Following A Medically Assisted Procreation (MAR) Management During A COVD-19 Pandemic Period PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Because of the physiological changes inherent in pregnancy, pregnant women with lower respiratory tract infections often have more worrisome outcomes compared to non-pregnant individuals, including a higher rate of hospital and intensive care unit admissions. |
UNIVERSITY HOSPITAL STRASBOURG FRANCE | 2020-08-01 |
| 64 | Antibodies Responses to SARS-CoV 2 Infection (COVID-19) in Hospitalized Patients. A Prospective Observational Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: 1.5. Why this clinical study? The prevalence of seropositivity following SARS-CoV 2 infection might have its own potential benefits in terms of predicting the end of pandemic and the validity of herd immunity. It is not clear if SARS-CoV 2 infection would have a long-lasting antibody-mediated immunity, and if the antibodies’ persistence is dependent on disease severity.depends on the severity of illness. If evidence is provided about the persistence of antibodies that is reflective of the protective immune response, serodiagnosis will be an important tool to identify individuals with various risk for infection, … |
MOHAMMED S ALSHAHRANI; | 2020-08-01 |
| 65 | Effectiveness of Remedesvir in SARS-CoV2 Patients Presenting at Mayo Hospital Lahore PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Currently, several drugs including Remdesivir, hydroxychloroquine, chloroquine, ritonavir+lopinavir, Tocilizumab, Arbidol and interferon are under randomised controlled trials (RCTs) for efficacy and/or safety evaluations in patients with COVID-19 in different countries. Remdesivir (GS-5734) is among these investigational drugs and some studies reported promising results. Remdesivir is a nucleotide analogue intravenous pro-drug developed by Gilead Sciences, an American biopharmaceutical company, … |
KING EDWARD MEDICAL UNIVERSITY | 2020-08-01 |
| 66 | Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Patients with diabetes have been listed as people at higher risk for severe illness from COVID-19. Moreover, the relationship between diabetes-related phenotypes and the severity of COVID-19 remains unknown. This observational study aims to to evaluate the risk of disease severity and mortality in association with diabetes in COVID-19 inpatients and identify the clinical and biological features associated with worse outcomes. |
RICCARDO BONADONNA; | 2020-07-30 |
| 67 | MSCT Chest in Suspected COVID-19 Patients in Correlation With Symptomology and Laboratory Findings PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The present study aimed to evaluate the accuracy of MSCT chest in the detection of COVID-19 cases and to correlate its diagnostic performance with that of the clinical presentation and CBC indices; using RT-PCR assays as a gold standard. |
GEHAN S. SEIFELDEIN; | 2020-07-30 |
| 68 | Does Therapeutic Plasma Exchange Have A Role in Resistant Cytokine Storm State Of COVID-19 Infection? PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This research is planned to illustrate the efficacy of Therapeutic Plasma Exchange (TPE) treatment in COVID-19 patients with resistant cytokine storm state. |
MOHAMED MAMDOUH MAHMOUD MOHAMED ELSAYED; | 2020-07-25 |
| 69 | Physiotherapy As A Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Coronavirus (CoViD-19) positive stroke survivors (SSv) with comorbidities faces possibility for mortality. Study reports success of physiotherapy in CoViD-19 positive SSv with multiple comorbidities. Methods: This clinical controlled study involve a minimum of 30 SSv and 30 age and sex-matched non-stroke individuals with multiple comorbidities with CoViD-19 status confirmed using Real-Time Quantitative-Polymerase Chain Reaction. The Cycle Threshold (CT) and nucleic acid content in the test sample (NA) will be recorded from the virology test results. Their exercise endurance, … |
CALEB ADEMOLA OMUWA GBIRI; | 2020-07-13 |
| 70 | Burnout, Anxiety, Depression, Stress (BADS) and Post-Trauma Stress Disorder (PTSD) in Healthcare Workers Exposed to COVID-19 Patients PF:9 Related Papers Related Patents Related Grants Related Experts View Highlight: The recent COVID-19 outbreak has put the health care workers on the frontline to interact and provide support to the patients. Based on previous disease outbreak-associated studies, it is evident that these individuals are at a high-risk of developing psychological distress such as burnout, anxiety, depression, and stress (BADS). Thus, the current study aims to evaluate the mental health outcomes of healthcare workers dealing with COVID-19 patients within Qatar and internationally, … |
ALI AIT HSSAIN; | 2020-07-11 |
| 71 | Seroprevalence of SARS-CoV 2 Among Asymptomatic Frontline Healthcare Workers During COVID 19: A Cross Sectional Study PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is about the current knowledge on the immunological changes observed in various healthcare workers in this part of the world, who remained asymptomatic while working in high exposure areas of COVID-19 infection. |
AMINA ASIF; | 2020-07-01 |
| 72 | Diagnostic Value of New- Covid 19 Antibodies Testing Among Laboratory Healthcare Workers PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: COVID-19 antibodies testing among healthcare workers to evaluate the role of Covid 19Ab testing as screening method for detection of covid 19 infections among laboratory health care workers ,assess the relationship between the infection with Covid 19 and different laboratory categories/area and assessemt of efficiency personal protective equipment (PPE) in different laboratory categories/area. |
SAMAR SALAH ELDIN ABDELRAHMAN SULTAN; | 2020-07-01 |
| 73 | Psychological Impact of COVID19 Among Doctors in Assiut University Hospitals PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: study aimed to investigate the psychological impact of corona virus among doctor in Assiut University Hospitals, mainly stress and burn out will be assessed |
MARIAM ROSHDY ELKHAYAT; | 2020-07-01 |
| 74 | Seroconversion in COVID-19 Recovered Population: An Observational Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study investigate the kinetics of IgG responses to both N and S proteins in the subjects who suffered from COVID 19 and then had recovered. |
AMINA ASIF; | 2020-07-01 |
| 75 | Efficacy and Safety of Anti-hepatitis C Drugs in The Treatment of COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: COVID 19 which started from a zoonotic transmission related to crowded markets was confirmed to have a high potential for transmission to close contacts on 20 January 2020 by the National Health Commission of China and it was announced as a pandemic by the WHO on 11 March 2020. There is currently no clinically proven specific antiviral agent available for SARS-CoV-2 infection. Supportive treatment, including oxygen therapy, conservation fluid management, and broad-spectrum antibiotics to cover secondary bacterial infection, remains the most important management strategy. Interestingly, … |
GAMAL ESMAT; | 2020-07-01 |
| 76 | Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: An Open Label Randomized Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: It is an established fact that, corona virus spread through the respiratory droplets. Colonization of the virus in oropharynx and/or nasopharynx is considered to be major factor for transmissibility of the virus through respiratory secretions. Preventing colonization of the virus by administrating povidone iodine in the nasal passage therefore, a rational thought which is supported by recent evidence of in-vitro virucidal action of povidone iodine in Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS CoV-2). Therefore, … |
MALA KHAN; | 2020-07-01 |
| 77 | A Randomised, Controlled, Phase 1 Study to Evaluate The Safety and Immunogenicity of A Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date, SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three hundred thousand people. |
DAVID GORDON; | 2020-06-30 |
| 78 | Prediction of Acute Kidney Injury in Patients With COVID-19 Associated Acute Respiratory Distress Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The two biomarkers determined in urine, Tissue Inhibitor of Metalloproteinases 2 (TIMP-2) and Insulin-like Growth Factor-Binding Protein 7 (IGFBP7), can indicate the occurrence of Acute kidney injury (AKI) in cardiac surgery and critically ill patients at an early stage. However, no data are available whether these parameters can also predict the occurrence of AKI in the context of COVID-19 infection. An early prediction of AKI can be helpful for the optimisation of therapeutic management to improve patient outcome and for the triage of patients. The aim of this observational study is to evaluate whether the biomarker [TIMP- … |
UNIVERSITY HOSPITAL MUENSTER | 2020-06-22 |
| 79 | PROSAIC-19 – Prospective Longitudinal Assessment in A COVID-19 Infected Cohort PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: DESIGN Longitudinal prospective observational multicentre study. Primary objective: Understand the immune mechanisms driving COVID-19 disease in patients with a history of lung disease |
IMPERIAL COLLEGE LONDON | 2020-06-18 |
| 80 | Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial InjuRY in COVID 19 (MEMORY- COVID) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Our understanding of the clinical manifestations of COVID-19 is growing on a daily basis and there is evidence that increased age, cardiovascular risk factors and cardiac comorbidity are strongly associated with poor outcomes. Furthermore, myocardial injury occurs and is associated with a much worse outcome and rapid increase in mortality. There have been several reports of myocarditis and heart failure following infection. The mechanisms of myocardial injury and its consequences are not well understood. In an ongoing peer-reviewed and funded study, … |
UNIVERSITY OF EDINBURGH | 2020-06-10 |
| 81 | A Randomised Double-blind Placebo-controlled Trial of Brensocatib (INS1007) in Patients With Severe COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent infection with SARS-CoV-2 and no therapeutic agent to treat COVID-19. This clinical trial is designed to evaluate the potential of Brensocatib (INS1007) as a novel host directed therapy for the treatment of adult patients hospitalized with COVID-19. The investigators hypothesise that Brensocatib, by blocking damaging neutrophil proteases, will reduce the incidence of acute lung injury and acute respiratory distress syndrome (ARDS) in patients with COVID-19, … |
UNIVERSITY OF DUNDEE | 2020-06-05 |
| 82 | Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: A phase II clinical trial will be carried out with the objective of studying the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection. Due to the high mortality of severe forms of SARS-CoV-2 and for ethical reasons, a control arm will not be included. Patients will be recruited by signing an informed consent and the baseline variables of interest will be recorded. Tocilizumab will be administered in one or two doses, depending on the case, … |
OSCAR GERARDO ARRIETA RODRÍGUEZ; | 2020-06-01 |
| 83 | Nebulized Heparin Vs. Placebo for The Treatment of COVID-19 Induced Lung Injury PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19 |
THOMAS SMOOT; | 2020-06-01 |
| 84 | Prevention of Coronavirus Disease (COVID-19) Outbreaks By Prophylactic Treatment With Nitazoxanide PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The new coronavirus outbreak has led to a public health emergency of international concern, putting all health organizations on high alert. As part of the hygienic measures, isolation and reinforcement cleaning strategies have been followed. It is known that special attention and efforts should be applied to protect or reduce transmission in susceptible populations, including the elderly or those with comorbidities.It has also been proposed a semaforization to classify patients with respiratory symptoms based on: Fever (38ºC or more), dry cough, headache, dyspnea, joint pain, muscle pain, sore throat, nose discharge, conjunctivitis, chest pain, diarrhea, anosmia, … |
HUGO MENDIETA ZERON; | 2020-05-21 |
| 85 | Exploring Brain Damages After COVID-19 Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Although direct evidence is currently lacking, the high identity between SARS-CoV-1 and SARS-CoV-2 suggests, that the latter viral strain could also infect the Central Nervous System (CNS). Indeed, some cases of SARS-COV2 encephalitis begin to be described and CNS damages are increasingly highlighted in the literature, … |
BERTRAND GLIZE; | 2020-05-19 |
| 86 | Incidence of Covid-19 in School Children During The Pandemic Period in Nice Related Papers Related Patents Related Grants Related Experts View Highlight: The Coronavirus disease 2019 (COVID-19) is causing a global pandemic with high morbidity and mortality among adults and mainly the elderly. Children seem to be little or not affected by this infection. It is estimated that children could be asymptomatic or pauci-symptomatic carriers and thus be vectors of the disease. This is why measures to close schools and confine populations have been decreed in a large number of countries, including France. However, there are only a few data on the prevalence of COVID19 disease in children. The deconfinement strategy depends on data on the prevalence of the disease, … |
FONDATION LENVAL | 2020-05-15 |
| 87 | Pilot Study on The Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy – COLOR 19) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Low-dose radiotherapy treatment delivered to both lungs in patients with immune-related pneumonia following COVID-19 infection is backed up by biological and clinical bases that justify its use as a possible therapeutic option in these patients. This is a preliminary exploratory study (non-pharmacological interventional) to evaluate the feasibility and tolerability of low-dose radiotherapy treatment of SARS-Cov-2 immune-mediated pneumonia, for the subsequent implementation of a phase II study.This is a preliminary, monocentric, single-arm, interventional, non-pharmacological exploratory study. All enrolled patients will be treated with low-dose radiotherapy. Participants will undergo irradiation of the lungs, … |
STEFANO MARIA MAGRINI; | 2020-05-10 |
| 88 | A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care (active) vs. standard of care alone (SoC), … |
TARIQ CHEEMA; | 2020-05-08 |
| 89 | Seroprevalence of SARS-Cov-2 Antibodies in Children – A Prospective Multicentre Cohort Study PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to SARS-CoV-2. |
THOMAS WATERFIELD; | 2020-05-06 |
| 90 | Efficacy and Safety of Convalescent Plasma Vs Human Immunoglobulin for The Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: On December 2019, a new human coronavirus infection (COVID-19) was detected in China. Its infectivity and virulence characteristics caused a rapid spread, being declared pandemic on March 2020. The mortality attributed to the infection ranges between 3 and 10%. Main risk factors are age, male sex, and chronic degenerative comorbidities. Due to the absence of therapeutic options, potential alternatives such as human immunoglobulin or plasma from convalescent patients have been administered. Due to the severity of the disease and the associated mortality, … |
CENTENARIO HOSPITAL MIGUEL HIDALGO | 2020-05-06 |
| 91 | Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty’s Hospital Infected and Diagnosed By SARS-Cov-2 With COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus infection. Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally. A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care and 20 control patients with standard of care. Treatment duration: 21 days. |
CATALYSIS SL | 2020-05-04 |
| 92 | Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is to verify if patients admitted to hospital in a medical division and in the intensive care unit for a COVID-19 infection are at higher risk of developing a VTE complication and if they actually present an increased hypercoagulable state. |
PAOLO SIMIONI; | 2020-05-01 |
| 93 | Impact of COVID-19 Infection During Pregnancy on Maternal and Fetal Outcome PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To asses impact of the COVID-19 infection during Pregnancy on maternal and fetal outcome in relation to gestational age. |
MOHAMED ELSIBAI ANTER; | 2020-05-01 |
| 94 | Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Nasal saline irrigations are a safe and commonly used mechanism to treat a variety of sinonasal diseases including sinusitis, rhinitis, and upper respiratory tract infections. When used properly, these irrigations are a safe and easy intervention available over the counter without a prescription. Additionally, baby shampoo has been found to be a safe additive functioning as a surfactant when a small amount is added to the saline rinses which may help augment clearance of the sinonasal cavity. While many systemic medications and treatments have been proposed for COVID-19, … |
KYLE KIMURA; | 2020-05-01 |
| 95 | Immune Responses to COVID-19 (SARS-CoV-2 Related Infection); Isolation of Human Neutralizing Monoclonal Antibodies for Therapeutics and Vaccine Design Approaches: A Prospective Monocentric Trial With Collaborative Sample Collection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: According to different projections, the COVID-19 outbreak currently happening in France and worldwide could result in millions of deaths in the absence of efficient therapies. The COVID-19 causative agent, the SARS-CoV-2, is a virus leading to respiratory system infections in human and for which there is currently no vaccine or treatment scientifically validated in clinical studies. In that context, therapeutic human neutralizing antibodies targeting the SARS-CoV-2 envelop glycoproteins and which enable inhibition of the viral replication represent an innovative therapeutic alternative with great potential. These antibodies are also critical tools for vaccine development. Simultaneously, … |
PASCAL POIGNARD; | 2020-04-30 |
| 96 | Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate The Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19. |
JANSSEN PHARMACEUTICA N V BELGIUM | 2020-04-24 |
| 97 | Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Covid-19 infection is due to SARS-CoV-2 member of the Coronavirus family represented by SARS- and MERS-CoVwith neuronal tropism capacity for the brainstem and thalami. Dexmedetomidine has(i) central antihypertensive (ii) sedative and (iii) neuroprotective properties and is often used during patient recovering after mechanical ventilation withdrawal. Dexmedetomidine administration could change the immunomodulatory profile of Covid-19 patients and reduce inflammatory response.CAM-ICU scores and Blood samples from Covid-19 ICU patients will be collected at 4 different timepoints (before Dexmedetomidine administration, at D2, D7 and M6) to analyse the inflammatory profile with different approaches:i) chromatin accessibility, ii) transcriptome analysis, … |
ALEXANDRE DEMOULE; | 2020-04-24 |
| 98 | A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate The Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This randomized blinded multi-center phase 2 trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19. Adults ≥18 years of age may participate. A total of 219 eligible subjects will be randomized in a 2:1 ratio to receive either high-titer anti-SARS-CoV-2 plasma or non-convalescent fresh frozen plasma (control plasma). |
MAX O’DONNELL; | 2020-04-21 |
| 99 | A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronavirus disease (COVID-19) pandemic has started to affect Saudi Arabia and is expected to cause a lot of morbidities and many patients, especially the elderly, will require intensive care unit (ICU) support to survive as its lethality increases with the increasing age. Development of a vaccine by pharmaceutical companies like Roche and antibody concentrates from convalescent patients’ plasma by Takeda will take 10-12 months to complete, … |
HANI AL-HASHMI; | 2020-04-18 |
| 100 | Treatment With Hydroxychloroquine Vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Coronaviruses (CoV) are positive-sense single-stranded RNA viruses that infect a wide range of hosts producing diseases ranging from the common cold to serious / fatal events. Nitazoxanide (NTZx) is a derivative of 5-nitrothiazole, synthesized in 1974 by Rosignol – Cavier. NTZx has powerful antiviral effects through the phosphorylation of protein kinase activated by double-stranded RNA, which leads to an increase in phosphorylated factor 2-alpha, an intracellular protein with antiviral effects. The purpose of this study is to contrast the beneficial effect of NTZx vs NTZx plus hydroxychloroquine in patients Coronavirus Disease (COVID-19) as well as against other treatments. |
HUGO MENDIETA ZERON; | 2020-04-06 |
| 101 | Association of The Neutrophil/Lymphocyte Ratio and Lymphocyte/Platelet Ratio With Pulmonary Complications and Mortality in COVID-19 Patients PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The Coronavirus Disease-19 (COVID-19) pandemic is currently a priority for health services worldwide. Unlike the Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) epidemic in 2012, the COVID-19 shows specific alterations in the white blood cell count, accentuated in severe cases, and with respiratory failure. Among the most relevant data are both lymphopenia, thrombocytopenia, and eosinopenia. The Neutrophil Lymphocyte Index has been beneficial in the evaluation of infectious respiratory processes, showing a sensitivity similar to scales such as CURB65 (Confusion, Uremia, Respiratory rate, BP, age ≥ 65 years). Because COVID-19 infection shows alterations in the blood cell ratio, … |
CHRISTIAN OMAR RAMOS-PEÑAFIEL; | 2020-03-30 |
| 102 | Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused By COVID-19: A Prospective, Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: In this multi-center, randomized, control study, the investigators will evaluate the efficacy and safety of glucocorticoid in combination with standard care for COVID-19 patents with Severe acute respiratory failure. |
PEKING UNION MEDICAL COLLEGE HOSPITAL | 2020-01-26 |
| 103 | Taipei City Hospital Linsen Chinese Medicine and Kunming Branch PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak. Main purpose: Retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2. Secondary purpose: If there are related side effects after taking Chinese medicine. |
CHUNG-HUA HSU; | 2020-01-01 |
| 104 | Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The Novel Coronavirus (2019-nCoV), also known as Wuhan coronavirus, causes the 2019-nCoV acute respiratory disease. |
GABRIELE SACCONE; | 2020-01-01 |
| 105 | Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The Novel Coronavirus (2019-nCoV), also known as Wuhan coronavirus, causes the 2019-nCoV acute respiratory disease. The number of patients infected by 2019-nCoV in Italy closely followed an exponential trend, and Italy reported the highest number of infected patients and deaths in the world excluding China. |
GABRIELE SACCONE; | 2020-01-01 |
| 106 | A Phase Ib Study to Determine The Safety and Immunogenicity of The Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Abstract: This is an open-label, dose escalation phase 1b trial to assess the safety and immunogenicity of the candidate ChAdOx1 MERS vaccine in healthy Middle Eastern adult volunteers aged … |
MOHAMMAD BOSAEED; | 2019-12-17 |
| 107 | Double-blind, Placebo-controlled Study With An Open Dose Selection Period for Assessing The Safety and Immunogenicity of The Drug BVRS-GamVac, A Vector Vaccine for The Prevention of The Middle East Respiratory Syndrome, Lyophilisate for The Preparation of A Solution for Intramuscular Administration, With The Participation of Healthy Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~34.5%. The aim of the study is to assess the safety and immunogenicity of adenoviral-based vaccine against MERS – BVRS-GamVac. |
DMITRY LYOZNOV; | 2019-11-07 |
| 108 | Double-blind, Placebo-controlled Study With An Open Dose Selection Period for Assessing The Safety and Immunogenicity of The Drug BVRS-GamVac-Combi, A Combined Vector Vaccine for The Prevention of The Middle East Respiratory Syndrome, Lyophilisate for The Preparation of A Solution for Intramuscular Administration, With The Participation of Healthy Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~34.5%. The aim of the study is to assess the safety and immunogenicity of heterologous adenoviral-based vaccine against MERS – BVRS-GamVac-Combi. |
TATIANA ZUBKOVA; | 2019-11-06 |
| 109 | Incidence of Iatrogenic Diseases on Toulon-La Seyne Sur Mer Hospital Emergency Consultations During Summer 2018 PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: French population grows older year after year: 24.3% people were over 60 years old in 2006 against 20.6% in 2000 and the expected number might be over 33% in 2050. The elderly suffer from lots of illnesses, so they usually take lots of drugs. Therefore, this drug use is most likely to have adverse drug reactions. Finally, according to Health Ministry, the number of emergency department consultations doubled from 1996 to 2016. Consequently, … |
CENTRE HOSPITALIER INTERCOMMUNAL DE TOULON LA SEYNE SUR MER | 2019-06-28 |
| 110 | Clinical Investigation to Assess The Performance of The Eureka Electric Breast Pump in Mothers Breastfeeding Their Healthy Term Infant PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Babies are the best in class in order to get human milk out of a lactating breast. With this in mind, Philips has developed the a new electric breast pump, attempting to mimic the babies sucking behavior. The new electric breast pump includes a new vacuum profile and 2 new expression kits. |
PHILIPS CONSUMER LIFESTYLE | 2019-05-17 |
| 111 | Detecting Soluble MER Levels After Myocardial Ischemia and Reperfusion Injury in Pediatric Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The relationship between the immune system and the myocardium after myocardial ischemia is an evolving field of research. Crosstalk occurs between macrophages and cardiac myocytes to promote cardio-protection and resolution of inflammation after myocardial ischemia and reperfusion injury (MI/R injury). Myeloid-epithelial-reproductive tyrosine kinase (MerTK), a member of the TAM family of tyrosine kinase receptors (Tyro-Axl-MerTK), is a macrophage receptor that mediates efferocytosis, anti-inflammatory signaling, and resolution of inflammation. After MI/R injury, intact MerTK is necessary for the phagocytosis of dead cardiac myocytes and to promote anti-inflammatory signaling. Proteolytic cleavage of MerTK to its inactive form, soluble MER, … |
ANN & ROBERT H LURIE CHILDREN’S HOSPITAL OF CHICAGO | 2019-05-10 |
| 112 | A Phase II Study Evaluating The Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open-label, single-arm multicenter, phase II study. The primary objective is to assess the efficacy of bemcentinib (BGB324) a highly selective inhibitor of the AXL receptor tyrosine kinase for the treatment of AML and MDS patients failing or being refractory to first line hypomethylating agent (HMA) treatment. Furthermore, safety, disease progression, treatment failure will be assessed. A total of 43 patients will be included in the trial. |
UWE PLATZBECKER; | 2018-12-20 |
| 113 | Phase I/IIa, Open-label, Dose Ranging Study to Evaluate The Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed By CELLECTRA® 2000 (Electroporation, EP) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The Middle East Respiratory Syndrome Coronavirus (MERS CoV), is a cause of severe and highly fatal lower respiratory tract infection, first identified in 2012. As of August 2018, there have been 2229 cases reported with a case fatality rate >35%. In 2015 an individual returning to South Korea served as the index case for an outbreak of 186 individuals, of who, >20% died. GLS-5300 is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein. This Phase I/IIa study will evaluate the safety, … |
GENEONE LIFE SCIENCE | 2018-08-28 |
| 114 | Assessment of Adherence to Gluten Free Diet in Children and Adolescents By Detection of Gluten Immunogenic Peptides in Faecal Samples and Nutritional Assessment. Retrospective Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To assess the adherence to gluten free diet by measuring faecal and urinary gluten immunogenic peptides (GIP). This will provide an objective measure for adherence. |
RAANAN SHAMIR; | 2018-06-19 |
| 115 | Marginal Zone Similar to B Lymphocytes in Peripheral Blood in Patients With Celiac Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This project is expected to confirm the hypothesis that hyposplenism in patients with celiac disease is not conditioned by a selective memory deficiency of B lymphocytes. Other objectives of project are: – determination of gliadin 33-mer in faecal and urine as indicators patient´s adherence to gluten-free diet – determination of citrulline in plasma as an indicator of the overall functional capacity enterocytes |
PROFF. JAN BURES; | 2018-06-01 |
| 116 | A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) – PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram negative bacteria. |
PFIZER | 2018-04-05 |
| 117 | A Phase I Study to Determine The Safety and Immunogenicity of The Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a clinical trial in which healthy volunteers will be administered an experimental MERS vaccine. The vaccine ChAdOx1 MERS will be administered alone both as a single administration and with a homologous prime-booster. |
ADRIAN V HILL; | 2018-03-14 |
| 118 | A Study of RXDX-106, An Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors Related Papers Related Patents Related Grants Related Experts View Highlight: This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit. This study will examine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of RXDX 106. |
SANDRA PIERINA D’ANGELO; | 2018-02-15 |
| 119 | Effects of Anesthesia Drugs on Neuronal Activity in The Basal Ganglia and Thalamus During Deep Brain Stimulation Electrode Implantation Surgery PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Deep brain stimulation (DBS) of different brain nuclei is a treatment for multiple brain disorders. The subthalamic nucleus (STN) and globus pallidus have been used to treat advanced Parkinson’s disease for a long time. The ventral intermediate nucleus of the thalamus is an effective target for treating essential tremor patients. STN and the internal segment of the globus pallidus are useful targets for treating dystonia. To achieve this optimal electrode localization, many centers perform electrophysiological mapping of the target nuclei using microelectrode recording (MER). This way they can achieve precise localization of the electrode. During the mapping procedure, … |
COREY A AMLONG; | 2017-12-01 |
| 120 | Metagenome Analysis of Intestinal Microbiome in Mortality and Morbidity of Preterm Infants PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is single center study. The investigators will try to know that relationships between intestinal microbiome and mortality in preterm infants and what relationships is between intestinal microbiome in preterm infants and morbidity, mortality. |
BYOUNGKOOK LEE; | 2017-07-25 |
| 121 | Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The implantation of a deep brain stimulator (DBS) is an established option to improve the symptoms of Parkinson’s disease (PD) in patients that do not respond adequately to medical therapy. Most centers perform this surgery using a technique that involves microelectrode recording (MER) of neuronal activity for localization of the target nucleus, microstimulation of identified targets, and neurological intraoperative testing in a cooperative patient. Dexmedetomidine, a α2-adrenergic receptors agonist, is a potent anxiolytic that acts at subcortical areas of the brain without involving GABA receptors. It provides excellent sedation without respiratory depression; also, … |
MARTINEZ-SIMON ANTONIO; | 2017-05-01 |
| 122 | Badanie Kliniczne Oceniające Bezpieczeństwo I Skuteczność Stosowania Stentów Szyjnych MER® W Rewaskularyzacji Tętnic Szyjnych PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of the study is to confirm, whether the MER® stent can be used, without limitations, for the endovascular carotid stenosis treatment in daily clinical practice. Eligible patients will undergo the procedure of the common or internal carotid artery stenting using MER® with proximal or distal neuroprotection. |
PIOTR ODROWĄŻ-PIENIĄŻEK; | 2016-10-01 |
| 123 | Evaluation of Directional Recording and Stimulation Using The SpiderSTN During The Implantation of DBS Leads Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to provide proof-of-concept that directional stimulation and directional recording, in an intraoperative setting, is perceivable in a subject. The tests will be performed using a dedicated intraoperative lead connected to an external neuro-recorder/stimulator, during a deep brain stimulation implantation surgery. |
CLAUDIO POLLO; | 2016-09-01 |
| 124 | MERS-CoV Infection TReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: A Multicenter, Placebo-controlled, Double-blind Randomized Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a placebo-controlled clinical trial to assess the efficacy and safety of a combination of lopinavir/ritonavir and Interferon beta-1b in hospitalized patients with MERS. |
KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER | 2016-07-01 |
| 125 | A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Middle East Respiratory Syndrome (MERS) is a newly discovered contagious and sometimes fatal respiratory virus. People often get MERS through close contact with an infected person. Scientists are worried that MERS may spread and cause more infections. There are no vaccines or treatments for MERS right now. Researchers think a new therapy called SAB-301 may be able to help. Antibodies are proteins the body makes to attack viruses. SAB-301 is made of antibodies made in cows to fight MERS. The antibodies are collected from plasma, … |
RICHARD T DAVEY; | 2016-05-28 |
| 126 | Phase I, Open-label, Dose Ranging Study to Evaluate The Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed By Electroporation in Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The Middle East Respiratory Syndrome Coronavirus (MERS CoV), a virus related to Severe Acute respiratory syndrome coronavirus (SARS CoV), was first recognized as a cause of severe pulmonary infection in 2012. Infection with MERS CoV has been diagnosed in more than 1600 individuals with a mortality rate between 35% and 40%. GLS-5300 is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein. This study will evaluate the safety of GLS-5300 at one of three dose levels following a three-injection vaccination regimen followed by electroporation. The study will also assess immune responses over a 1 year period with respect to the generation of antibody and cellular responses. |
KAYVON MODJARRAD; | 2016-02-01 |
| 127 | Determination of EC50 of Anesthetics During Microelectric Recording in Patients Receiving Deep Brain Stimulation Under Anesthesia PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigators determine the half maximum effective concentration (EC50) of the Cet value of propofol in target-controlled infusion (TCI) when co-administered with dexmedetomidine for the maintenance of general anesthesia during microelectrode recording in the deep brain surgery in patients with Parkinson’s disease. |
VGHTPE USER; | 2016-01-29 |
| 128 | MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure and to healthy controls. |
CHRISTINE BERNSMEIER; | 2015-08-27 |
| 129 | Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The investigators aim to do serosurvey of healthcare-personnel who had participated in treatment of confirmed patients of Middle-East respiratory syndrome. The investigators collected the base-line (pre-exposure) serum of healthcare-personnel in a few centers, and will collect the post-exposure serum from about 25-30 centers in which confirmed MERS patients had been treated. The investigators will deduct the seroprevalence of MERS-CoV IgG among the healthy healthcare-personnel, and calculate the sero-conversion rate if possible. The investigators will subdivided the seroprevalence according to the degree of exposure and preparedness of personal protective equipment. |
HEE JUNG CHOI; | 2015-08-01 |
| 130 | Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) and Infection Control Experiences in A Medical Institution of South Korea PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aimed to analysis the characteristics of MERS transmission and the effect of our institutional personal protective equipment on the controlling the MERS at a tertiary Korean Hospital. |
SANG O; | 2015-06-01 |
| 131 | A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open-label Phase 2 randomized study that will examine the use of the study agents, CMB305 (sequentially administered LV305 which is a dendritic cell-targeting viral vector expressing the New York Esophageal Squamous Cell Carcinoma 1 gene [NY-ESO-1] and G305 which is a NY-ESO-1 recombinant protein plus glucopyranosyl lipid adjuvant-stable emulsion [GLA-SE]) in combination with atezolizumab or atezolizumab alone, in participants with locally advanced, relapsed or metastatic sarcoma (synovial or myxoid/round cell liposarcoma) expressing the NY-ESO-1 protein. There is no formal primary hypothesis for this study. |
IMMUNE DESIGN | 2015-04-29 |
| 132 | A Phase 1/2 Single-ascending and Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-CC5 in Healthy Adult Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-CC5 in healthy adult volunteers and subjects with PNH |
ALNYLAM PHARMACEUTICALS | 2015-01-01 |
| 133 | Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A highly pathogenic human coronavirus causing respiratory disease emerged in Saudi Arabia in 2012. This viral infection termed Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with high mortality rate in approximately 36% of reported patients. The World Health Organization (WHO) reported 1,374 laboratory-confirmed worldwide infections, including at least 490 related deaths, from September, 2012, to July 24, 2015.2 The higher incidence of MERS-CoV infections in Saudi Arabia may be related to multiple factors, including seasonality, increased proactive screening, poor infection control measures, low relative humidity, and high temperature. Infected patients with MERS-CoV usually have abnormal findings on chest radiography, … |
ANEES SINDI; | 2012-09-01 |
| 134 | Onset and Offset of Von Willebrand Factor Multimemirization Defects in Cardiovascular Disease: The Case of The Molecular Sensor of Blood Flow PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The WITAVI study was designed to explore the kinetic and associated outcome of Von Willebrand Factor-multimerizaton defects associated with devices in cardiovascular diseases. |
ERIC VAN BELLE; | 2012-08-01 |
| 135 | A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer. |
EMD SERONO | 2011-10-24 |
| 136 | Clinical Outcomes of Deep Brain Stimulator Electrodes Placed Using Intraoperative Computed Tomography and Frameless Stereotaxis Versus Microelectrode Recording and Frame-based Stereotaxis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine whether performing deep brain stimulation surgery for Parkinson’s disease using intraoperative imaging and frameless stereotaxis is noninferior to using frame-based stereotaxy and microelectrode recording. |
MATTHEW BRODSKY; | 2011-09-01 |
| 137 | Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: – Increased clinical attention has been paid to the evaluation and management of bioterrorism-related illness (such as anthrax infection) and emerging infectious diseases (such as Severe Acute Respiratory Syndrome \[SARS\] and new strains of influenza). However, evaluation and treatment data for these illnesses are often limited because human infections to date have been relatively limited. Further knowledge about diseases of bioterrorism concern and emerging infectious diseases may lead to more effective forms of therapy to prevent disease-related illnesses and deaths. Objectives: – To apply standardized, documented, and carefully monitored evaluation and treatment methods for bioterrorism- … |
RICHARD T DAVEY; | 2011-08-04 |
| 138 | Phase 0 Monitoring of Gluten-free Diet Compliance in Celiac Patients By Assessment of Gliadin 33-mer Equivalent Epitopes in Feces PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to monitor of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces. |
CAROLINA SOUSA MARTIN; | 2011-04-01 |
| 139 | Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying blood and tumor tissue samples from young patients with acute myeloid leukemia. |
KRISTEN M. EISENMAN; | 2009-09-01 |
| 140 | Randomized Phase III Trial Comparing The Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®)) Alone and in Combination With Epoetin Alfa (Procrit®)) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. |
AMIT K VERMA; | 2009-01-29 |
| 141 | A Multi-Center Phase II Study to Compare MER-101 (20mg) Tablets To Intravenous Zometa 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy. The effects will be monitored on a weekly basis by measuring various markers of bone metabolism. Patients to be enrolled will be those who have not received any previous bisphosphonate therapy. The study will be carried out on prostate cancer patients who are no longer on hormone therapy. Treatment in the study will be for a 2-month period. |
MERRION PHARMACEUTICALS | 2008-02-01 |
| 142 | Oral Administration of The GnRH Antagonist Acyline in Normal Men Part II: Multiple-dose Pharmacokinetics (Acyline-7/MER 104-02) Related Papers Related Patents Related Grants Related Experts View Highlight: We propose oral dosing of gastrointestinal permeation enhancement technology [GIPET] enhanced oral acyline at 20 mg everyday for one week to determine the steady-state (multiple-dose) pharmacokinetics of oral acyline in four normal, healthy young men. |
JOHN K AMORY; | 2008-01-01 |
| 143 | Lowering VT and Increasing PEP During One-Lung Ventilation (OLV), Impact on Oxygenation PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: During general anesthesia, airway closure and the formation of atelectasis impair oxygenation. During one-lung ventilation, large tidal volumes are used to resume atelectasis with a risk of regional over distension and Ventilator-Induced Lung Injury (VILI). The reduction in TV should reduce the occurrence of VILI but lead to a consistent alveolar derecruitment. This harmful effect may be counteracted by PEP. We, therefore, study the impact on oxygenation, of increasing PEP during OLV, in order to maintain alveolar recruitment when TV is reduced. |
HADRIEN ROZE; | 2007-11-01 |
| 144 | A Pilot Dose Finding Study of MUC1 Vaccine in Conjunction With Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) or HiltonolTM in Patients With Recurrent And/or Advanced Prostate Cancer PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also known as HiltonolTM, in boosting the body’s immune system’s response to an experimental vaccine therapy (called the MUC-1 vaccine). |
OLIVERA FINN; | 2006-06-01 |
| 145 | Food and Diet Based Validations of A Nutrient Profiling System for Reformulation in Two Nationally Representative Surveys PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: The objectives of the study are to assess the validity of Nestlé reformulation criteria in two national dietary surveys: the US NHANES 2011, and the French INCA2 2006-07. |
NESTLÉ | 2006-01-01 |
| 146 | Efferocytosis (Clearance of Apoptotic Cells By Phagocytosis) and Autoimmune Diseases in Human PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Over the past few years, growing evidences revealed that clearance of apoptotic cells by phagocytosis can result in powerful anti-inflammatory and immunosuppressive effects. In vivo, apoptotic cells are cleared rapidly by neighboring cells, macrophages and related scavengers. Defective clearance of apoptotic cells has been linked closely to autoimmunity and persistent inflammatory disease. Several phagocytic receptors, bridging molecules produced by phagocytes and ‘eat-me’ signals on apoptotic cells are coordinately involved in mediating clearance of apoptotic cells. Complement receptors (CR3, CR4), collection, CD14, CD36 (Class B scavenger receptor), class A scavenger receptor, asialoprotein receptor, … |
CHUNG-YI HU; | 2006-01-01 |
| 147 | Are Paraspinous Intramuscular Injections of Botulinum Toxin A (BoNT-A) Efficient in The Treatment of Chronic Low-back Pain? PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Studying the therapeutic effect of paravertebral injections of BoNT-A (botulinum toxin A) requires further studies to confirm the reported short-term therapeutic effect and to determine potential predictive factors of efficacy. |
MATTHIEU DE SEZE; | 2003-11-18 |